No Data
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Raises Target Price to $73
Harrow Health: Promising Growth Trajectory and Compelling Investment Opportunity
B. Riley Adjusts Price Target on Harrow to $73 From $50, Maintains Buy Rating
Express News | Harrow Inc - FDA Agrees to Melt-300 Phase 3 Special Protocol Assessment
Express News | Harrow Inc - Topline Readout Expected in Q4 2024
Express News | Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
loading...